CDK9-IN-7 |
Catalog No.GC35636 |
CDK9-IN-7 (compuesto 21e) es un inhibidor de CDK9/ciclina T selectivo, muy potente y activo por vÍa oral (IC50=11 nM), que muestra una mayor potencia que otras CDK (CDK4/ciclinaD=148 nM; CDK6/ciclinaD= 145 nM). CDK9-IN-7 muestra actividad antitumoral sin toxicidad evidente. CDK9-IN-7 induce la apoptosis de las células NSCLC, detiene el ciclo celular en la fase G2 y suprime las propiedades de tallo del NSCLC.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2369981-71-3
Sample solution is provided at 25 µL, 10mM.
CDK9-IN-7 (compound 21e) is a selective, highly potent, and orally active CDK9/cyclin T inhibitor (IC50=11 nM), which exhibits more potent over other CDKs (CDK4/cyclinD=148 nM; CDK6/cyclinD=145 nM). CDK9-IN-7 shows antitumor activity without obvious toxicity. CDK9-IN-7 induces NSCLC cell apoptosis, arrests the cell cycle in the G2 phase, and suppresses the stemness properties of NSCLC[1]. CDK9/cyclinT1|11 nM (IC50)|CDK4/cyclin D|148 nM (IC50)|CDK6/cyclinD|145 nM (IC50)
CDK9-IN-7 displays exceptional potency against NSCLC cell lines, especial A549 and H1299 with IC50 values less than 0.5 µM. In the drug-resistant NSCLC cell line H1975, CDK9-IN-7 also exhibits good inhibition potency with an IC50 value of 0.837 µM[1].
[1]. Wang X, et al. Novel cyclin-dependent kinase 9 (CDK9) inhibitor with suppression of cancer stemness activity against non-small-cell lung cancer. Eur J Med Chem. 2019 Jul 25;181:111535.
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *